BioVirtus (Poland)

Recent papers from BioVirtus (Poland)

1. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)ESMO Open · 2024
2. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialNature Medicine · 2023
3. A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology · 2021
4. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairmentCancer Chemotherapy and Pharmacology · 2021
5. Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studiesPharmacological Reports · 2021
6. Evaluation of Drug–Drug Interactions of Rucaparib and CYP 1A2, CYP 2C9, CYP 2C19, CYP 3A, and P‐gp Substrates in Patients With an Advanced Solid TumorClinical and Translational Science · 2018